Please assess the completion status of the following clinical trial:

Trial Title: Cetrotide Treatment Optimization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normo-ovulatory women \< 39 years with an indication for IVF or ICSI~Exclusion Criteria:~* More than 2 previous unsuccessful IVF/ICSI cycles~* BMI \> 32 kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- CD2 (Type: EXPERIMENTAL): Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
- CD6 (Type: EXPERIMENTAL): Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).